Latest 10-K annual reports
NASDAQ
GigCapital7 Corp. files an amendment to its annual report on Form 10-K to include the company's stock trading policy and insider trading prohibition, as well as its policy for recovery of erroneously awarded incentive compensation.
NYSE
BlackSky Technology Inc. files Amendment No. 1 to its 2024 Annual Report on Form 10-K to include information previously omitted regarding directors, executive officers, compensation, security ownership, related transactions, and principal accountant fees.
NASDAQ
Cross Country Healthcare files an amendment to its 2024 Annual Report to include detailed information on directors, executive officers, corporate governance, and executive compensation.
Investcorp AI Acquisition Corp. files its 10-K, highlighting its ongoing search for a business combination and expressing uncertainty about its ability to continue as a going concern.
NASDAQ
CTRN
Citi Trends INC10-K: Citi Trends Navigates Transformation Amidst Economic Headwinds, Focuses on African American Customer
Citi Trends reports a net loss for fiscal year 2024 but shows signs of recovery with improved comparable store sales in the second half, driven by a sharpened focus on its core African American customer base and strategic initiatives.
CMRX
Chimerix INC10-K/A: Chimerix Amends Annual Report Following $935 Million Acquisition Agreement with Jazz Pharmaceuticals
Chimerix files an amendment to its 2024 annual report to include Part III information due to the pending acquisition by Jazz Pharmaceuticals for $935 million.
OQB
VPRB
Vpr Brands, LpVPR Brands, LP's 2024 annual report reveals a revenue decrease alongside ongoing efforts to address internal control deficiencies, despite positive developments in patent settlements.
QRON
Qrons INC10-K: Qrons Inc. Secures $250,000 in Convertible Debt Financing to Fuel Cognitive Wellness Expansion
Qrons Inc. enters into a series of note purchase agreements to secure $250,000 in convertible debt financing, aimed at supporting general working capital and expanding its cognitive wellness business.
OQB
Omnitek Engineering Corp. files an amendment to its annual report to correct the date and signature of the auditor's report, with no changes to the original financial information.
NYSE
Movado Group restates prior financial statements due to misconduct in its Dubai branch, impacting sales recognition in the Middle East, India, and Asia Pacific region.
OTC.Pink
Kuber Resources Corporation amends its 10-K filing to include iXBRL, reports a net income of $386,267 for FY 2024, and finalizes the acquisition of Gongfa Materials.
OID
Sentient Brands Holdings Inc. files its 10-K for the year ended December 31, 2024, reporting a net loss and a going concern warning, while also announcing an acquisition agreement with American Industrial Group.
OTC.Pink
MLRT
Metalert, INCMetAlert Inc.'s 2024 annual report reveals a year of strategic shifts, including an acquisition and product line expansion, amidst ongoing financial difficulties and a going concern warning.
NASDAQ
Solidion Technology's 2024 10-K filing reveals a year of strategic shifts, including a business combination, advancements in battery technology, and a foray into Bitcoin as a treasury asset, alongside ongoing financial losses and internal control weaknesses.
Aquaron Acquisition Corp.'s annual report reveals delisting from Nasdaq, ongoing efforts to complete a merger with Huture Ltd., and substantial doubt about its ability to continue as a going concern.
OID
BRGX
Bioregenx, INCBioRegenx, Inc. files an amended 10-K to correct a transcription error in the consolidated statement of deficit, while reporting a substantial increase in net loss for the fiscal year ended December 31, 2024.
OTC.Pink
MSP Recovery's 10-K filing reveals substantial doubt about its ability to continue as a going concern, despite ongoing restructuring and financing efforts.
NASDAQ
Society Pass Inc. reports a net loss for fiscal year 2024, but shows improved cost control and a shift towards digital marketing.
OTC.Pink
Video River Networks reports its FY24 results, highlighting a shift towards Electric Vehicle (EV) acquisitions while acknowledging substantial doubt about its ability to continue as a going concern.
OTC.Pink
AppSoft Technologies' 2024 10-K filing reveals minimal business operations, no revenue, continued net losses, and substantial doubt about the company's ability to continue as a going concern.
AMEX
EON Resources Inc.'s 10-K filing reveals a year of operational shifts, financial challenges, and strategic realignments, including a going concern warning and a restatement of previous financials.
NASDAQ
Onfolio Holdings Inc. saw a 50% increase in revenue and a significant reduction in operating loss in 2024, driven by strategic acquisitions and operational improvements, setting the stage for potential sustained profitability.
NASDAQ
10-K/A: Research Frontiers Files Amendment to 10-K to Include Executive Compensation Clawback Policy
Research Frontiers Incorporated files an amendment to its annual report to include its Executive Compensation Recovery (Clawback) Policy, as required by SEC and NASDAQ regulations.
NASDAQ
Rain Enhancement Technologies Holdco outlines its share capital, warrant redemption procedures, and anti-takeover provisions in its recent 10-K filing.
Iris Acquisition Corp's 10-K filing reveals challenges in completing a business combination by June 30, 2025, alongside material weaknesses in internal controls.
OID
10-K: Natures Miracle Holding Inc. Reports Losses in 2024 10-K Filing; Faces Going Concern Uncertainty
Natures Miracle Holding Inc.'s 2024 10-K filing reveals substantial operating losses and doubts about the company's ability to continue as a going concern, despite a slight revenue increase.
OID
10-K: Authentic Holdings Inc. Reports Significant Losses and Going Concern Uncertainty in 10-K Filing
Authentic Holdings Inc.'s 10-K filing reveals substantial losses, a working capital deficit, and significant debt, raising doubts about the company's ability to continue as a going concern.
AMEX
The Arena Group Holdings, Inc. reports a significant net loss for fiscal year 2024, impacted by discontinued operations and strategic realignments, while navigating a challenging economic landscape.
AMEX
Kairos Pharma's 2024 10-K filing details the company's ongoing clinical trials, financial status, and strategic focus on developing cancer therapeutics.
ECD Automotive Design saw a revenue increase in 2024, but its net loss also significantly widened compared to the previous year.